These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27939073)

  • 1. Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population-based Data.
    He J; Albertsen PC; Moore D; Rotter D; Demissie K; Lu-Yao G
    Eur Urol; 2017 May; 71(5):760-763. PubMed ID: 27939073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.
    Thomsen FB; Folkvaljon Y; Brasso K; Loeb S; Robinson D; Egevad L; Stattin P
    J Surg Oncol; 2016 Nov; 114(6):664-670. PubMed ID: 27511833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
    Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
    Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
    BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.
    Loeb S; Folkvaljon Y; Robinson D; Lissbrant IF; Egevad L; Stattin P
    Eur Urol; 2016 Jun; 69(6):1135-41. PubMed ID: 26707871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.
    Leapman MS; Cowan JE; Simko J; Roberge G; Stohr BA; Carroll PR; Cooperberg MR
    Eur Urol; 2017 May; 71(5):750-759. PubMed ID: 27940155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ISUP Group 4 - a Homogenous Group of Prostate Cancers?
    Lu TC; Moretti K; Beckmann K; Cohen P; O'Callaghan M
    Pathol Oncol Res; 2018 Oct; 24(4):921-925. PubMed ID: 29079965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
    Lu-Yao GL; Albertsen PC; Moore DF; Lin Y; DiPaola RS; Yao SL
    Eur Urol; 2015 Nov; 68(5):805-11. PubMed ID: 25800944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
    Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Becker A; Chun FKH; Karakiewicz PI
    Prostate; 2022 May; 82(6):687-694. PubMed ID: 35188982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?
    Mahal BA; Muralidhar V; Chen YW; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Trinh QD; Nguyen PL
    BJU Int; 2016 Jul; 118(1):95-101. PubMed ID: 26207642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment.
    Pompe RS; Davis-Bondarenko H; Zaffuto E; Tian Z; Shariat SF; Leyh-Bannurah SR; Schiffmann J; Saad F; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Prostate; 2017 May; 77(6):686-693. PubMed ID: 28156003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of prostate cancer specific mortality after radical prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy Registry.
    Bolton DM; Papa N; Ta AD; Millar J; Davidson AJ; Pedersen J; Syme R; Patel MI; Giles GG
    BJU Int; 2015 Oct; 116 Suppl 3():66-72. PubMed ID: 26176738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
    Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
    Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
    Yang DD; Muralidhar V; Nguyen PL; Buzurovic I; Martin NE; Mouw KW; Devlin PM; Trinh QD; Orio PF; King MT
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):904-911. PubMed ID: 29063853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
    Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.
    Cazzaniga W; Garmo H; Robinson D; Holmberg L; Bill-Axelson A; Stattin P
    BJU Int; 2019 Mar; 123(3):421-428. PubMed ID: 30253031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
    Aizer AA; Chen MH; Hattangadi J; D'Amico AV
    BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
    Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
    Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database.
    Grossfeld GD; Chang JJ; Broering JM; Li YP; Lubeck DP; Flanders SC; Carroll PR
    J Urol; 2001 Mar; 165(3):851-6. PubMed ID: 11176485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.